Free Trial

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $16.25 Consensus Target Price from Analysts

Ocular Therapeutix logo with Medical background

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $16.25.

Several equities research analysts have issued reports on the stock. Needham & Company LLC lowered their price target on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. William Blair started coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an "outperform" rating on the stock. Royal Bank Of Canada assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price target for the company. HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Finally, JMP Securities set a $19.00 price objective on Ocular Therapeutix in a report on Tuesday, March 4th.

Check Out Our Latest Stock Report on Ocular Therapeutix

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,219 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total value of $152,352.42. Following the completion of the transaction, the insider now owns 3,499,099 shares in the company, valued at approximately $25,123,530.82. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard L. Md Lindstrom purchased 10,000 shares of the firm's stock in a transaction that occurred on Thursday, May 8th. The shares were acquired at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares in the company, valued at $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 29,079 shares of company stock worth $208,739 over the last ninety days. Corporate insiders own 2.30% of the company's stock.

Institutional Trading of Ocular Therapeutix

Several large investors have recently made changes to their positions in OCUL. GF Fund Management CO. LTD. bought a new position in shares of Ocular Therapeutix in the fourth quarter valued at about $28,000. Atlas Capital Advisors Inc. bought a new position in shares of Ocular Therapeutix in the fourth quarter worth about $43,000. Brooklyn Investment Group raised its stake in shares of Ocular Therapeutix by 151.5% in the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 3,155 shares during the last quarter. AlphaQuest LLC acquired a new position in shares of Ocular Therapeutix during the fourth quarter worth approximately $53,000. Finally, GAMMA Investing LLC grew its stake in shares of Ocular Therapeutix by 6,760.0% during the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 8,112 shares during the last quarter. Institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Stock Performance

Shares of OCUL stock traded up $0.03 during mid-day trading on Friday, reaching $8.33. The stock had a trading volume of 1,643,504 shares, compared to its average volume of 1,440,929. The firm's 50 day simple moving average is $7.82 and its 200 day simple moving average is $7.86. The company has a quick ratio of 10.14, a current ratio of 10.22 and a debt-to-equity ratio of 0.26. Ocular Therapeutix has a one year low of $5.79 and a one year high of $11.78. The firm has a market cap of $1.33 billion, a PE ratio of -7.24 and a beta of 1.42.

About Ocular Therapeutix

(Get Free Report

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Recommended Stories

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Should You Invest $1,000 in Ocular Therapeutix Right Now?

Before you consider Ocular Therapeutix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocular Therapeutix wasn't on the list.

While Ocular Therapeutix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines